Haemonetics CEO granted 78,344 RSUs

Haemonetics Corp President & CEO Christopher Simon reported compensation-related equity activity.

Rhea-AI Filing Summary

Haemonetics Corp President & CEO Christopher Simon reported compensation-related equity activity. He received an award of 78,344 shares of common stock in the form of restricted stock units that vest over three years. On the same date, 9,681 shares were withheld to cover tax obligations tied to previously vesting RSUs, and his reported direct holdings after these transactions were in the hundreds of thousands of shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Simon, Christopher

Role President & CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	9,681	$56.29	$545K
Grant/Award	Common Stock	78,344	$0.00	$0.00

Holdings After Transaction: Common Stock — 444,704 shares (Direct)

Footnotes (4)

1. F1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
2. F2. This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
3. F3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
4. F4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Key Figures

RSU award: 78,344 shares Tax withholding shares: 9,681 shares Withholding price: $56.29 per share +4 more

7 metrics

RSU award 78,344 shares Common stock RSUs granted on 2026-05-15

Tax withholding shares 9,681 shares Shares withheld for tax obligations at $56.29 per share

Withholding price $56.29 per share Value used for tax-withholding disposition

Holdings after RSU grant 444,704 shares Direct common stock holdings following the award entry

Holdings after tax withholding 366,360 shares Direct common stock holdings following tax-withholding disposition entry

ESPP purchase 497 shares Shares purchased under 2007 Employee Stock Purchase Plan on 2026-04-30

RSU vesting pattern 40% / 40% / 20% Annual vesting over three anniversaries of grant date

Key Terms

restricted stock units ("RSUs"), Employee Stock Purchase Plan, Long-Term Incentive Compensation Plan, tax obligations, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Employee Stock Purchase Plan financial

"497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Long-Term Incentive Compensation Plan financial

"RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

tax obligations financial

"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units"

contingent right financial

"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Haemonetics (HAE) CEO Christopher Simon report on this Form 4?

Christopher Simon reported a grant of 78,344 shares of common stock in the form of restricted stock units. These RSUs were issued under Haemonetics’ long-term incentive plan and represent a compensation award rather than an open-market purchase.

How do the new Haemonetics (HAE) RSUs for the CEO vest over time?

The CEO’s new RSUs vest in three annual installments. Forty percent of the total award vests on the first anniversary of grant, another forty percent on the second anniversary, and the remaining twenty percent on the third anniversary, subject to the plan’s conditions.

Why were 9,681 Haemonetics (HAE) shares disposed of in this insider filing?

The 9,681 shares were withheld to satisfy tax obligations on vesting RSUs. This tax-withholding disposition is a non-market event where shares are delivered to cover taxes owed on previously granted restricted stock units.

>How many Haemonetics (HAE) shares did Christopher Simon hold after these transactions?

The filing shows hundreds of thousands of shares directly held after the reported transactions. One line reports 444,704 shares following the RSU grant, while another shows 366,360 shares following the tax-withholding disposition, reflecting different steps in the sequence.

What does each Haemonetics (HAE) RSU in this award represent?

Each RSU represents a contingent right to receive one share of Haemonetics common stock when vested. Once vesting conditions are met, the company issues an equivalent number of shares to the reporting person under the plan.

Did the Haemonetics (HAE) CEO buy any shares through an employee stock purchase plan?

The filing notes that 497 shares were purchased under Haemonetics’ 2007 Employee Stock Purchase Plan. This purchase is included in the total number of shares reported as held by Christopher Simon, alongside unvested RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 05:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon, Christopher

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		F		9,681(1)	D	$56.29	366,360(2)	D
Common Stock	05/15/2026		A		78,344(3)	A	(4)	444,704(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

2. This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Mr. Simon	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)